Online Inquiry
TP53 (-/-); BRAF (V600K/+) Cell Line
SPL-00694
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| TP53 (-/-); BRAF (V600K/+) |
| Target Information | |
|---|---|
| Target Name | B-Raf |
| Gene Abbr. | BRAF |
| Gene ID | 673 |
| Full Name | B-Raf proto-oncogene, serine/threonine kinase |
| Alias | B-RAF1, B-raf, BRAF1, NS7, RAFB1 |
| Species | Human |
| Genomic Locus | 17p13.1; 7q34 |
| Introduction | This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008]. |
| Product Details | |
|---|---|
| Cell Line Model | MCF10A |
| Genotype | TP53 (-/-); BRAF (V600K/+) |
| Description | TP53 (-/-); BRAF (V600K/+) |
| Parental ATCC ID | CRL-10317 |
| STR Profile | Amelogenin: X; CSF1PO: 10,12; D13S317: 8,9; D16S539: 11,12; D5S818: 10,13; D7S820: 10,11; THO1: 8,9.3; TPOX: 9,11; vWA: 15,17; ATCC |
| Disease | Epithelial |
| Tissue | Breast |
| Gender | Female |
| Key Endogenous Mutations | none listed |
| CVT Selection Condition | G418 resistant - 0.1 mg/mL |
| Cell Number | 1x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Culture Medium | DMEM/F-12 including 2.5 mM L-glutamine and 15 mM HEPES, supplemented with 5% horse serum, 10 µg/mL insulin, 20 ng/mL hEGF, 0.5 µg/mL hydrocortisone, 0.1 µg/mL cholera toxin. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.